Zacks: Denali Therapeutics Inc (DNLI) Given Average Recommendation of “Buy” by Brokerages

Denali Therapeutics Inc (NASDAQ:DNLI) has earned an average broker rating score of 1.83 (Buy) from the three brokers that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a hold recommendation, one has assigned a buy recommendation and one has assigned a strong buy recommendation to the company.

Brokers have set a twelve-month consensus target price of $24.67 for the company and are expecting that the company will post ($0.27) earnings per share for the current quarter, according to Zacks. Zacks has also given Denali Therapeutics an industry rank of 185 out of 265 based on the ratings given to related companies.

How to Become a New Pot Stock Millionaire

Several equities research analysts recently weighed in on DNLI shares. Goldman Sachs started coverage on Denali Therapeutics in a report on Tuesday, January 2nd. They issued a “neutral” rating for the company. JPMorgan Chase & Co. started coverage on Denali Therapeutics in a report on Tuesday, January 2nd. They issued an “overweight” rating and a $24.00 price objective for the company. Morgan Stanley started coverage on Denali Therapeutics in a report on Tuesday, January 2nd. They issued an “overweight” rating and a $25.00 price objective for the company. Finally, Evercore ISI started coverage on Denali Therapeutics in a report on Tuesday, January 2nd. They issued an “outperform” rating and a $23.00 price objective for the company.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Crestline Management LP purchased a new position in shares of Denali Therapeutics during the fourth quarter worth about $321,782,000. Millennium Management LLC purchased a new position in shares of Denali Therapeutics during the fourth quarter worth about $1,475,000. Bridger Management LLC purchased a new position in shares of Denali Therapeutics during the fourth quarter worth about $4,888,000. Goldman Sachs Group Inc. purchased a new position in shares of Denali Therapeutics during the fourth quarter worth about $2,189,000. Finally, Wolverine Asset Management LLC purchased a new position in shares of Denali Therapeutics during the fourth quarter worth about $249,000. 65.45% of the stock is owned by institutional investors.

Denali Therapeutics stock traded up $0.17 during midday trading on Friday, hitting $21.34. The stock had a trading volume of 465,051 shares, compared to its average volume of 386,555. Denali Therapeutics has a 12 month low of $14.72 and a 12 month high of $25.79.

Denali Therapeutics (NASDAQ:DNLI) last released its earnings results on Monday, March 19th. The company reported ($0.74) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.27) by ($0.47). research analysts predict that Denali Therapeutics will post -0.87 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This report was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/3300568/zacks-denali-therapeutics-inc-dnli-given-average-recommendation-of-buy-by-brokerages.html.

Denali Therapeutics Company Profile

Denali Therapeutics Inc is a biotechnology company. The Company is focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and others. The Company is developing a diversified portfolio of therapeutics, based on scientific insights into the genetic causes and biological processes underlying neurodegenerative disease.

Get a free copy of the Zacks research report on Denali Therapeutics (DNLI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

$1.14 Earnings Per Share Expected for Pentair  This Quarter
$1.14 Earnings Per Share Expected for Pentair This Quarter
Somewhat Positive News Coverage Somewhat Unlikely to Affect Heat Biologics  Stock Price
Somewhat Positive News Coverage Somewhat Unlikely to Affect Heat Biologics Stock Price
Walmart Inc  Expected to Announce Quarterly Sales of $120.13 Billion
Walmart Inc Expected to Announce Quarterly Sales of $120.13 Billion
Transcontinental  Upgraded to “Outperform” by Royal Bank of Canada
Transcontinental Upgraded to “Outperform” by Royal Bank of Canada
Mosaic Capital  Downgraded to Hold at Canaccord Genuity
Mosaic Capital Downgraded to Hold at Canaccord Genuity
Weibo  Upgraded by Zacks Investment Research to Buy
Weibo Upgraded by Zacks Investment Research to Buy


© 2006-2018 Ticker Report. Google+.